Detalhe da pesquisa
1.
John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
Eur J Neurol
; 24(9): 1196-1199, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28707781
2.
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Mult Scler Relat Disord
; 87: 105670, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772150
3.
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
Mult Scler Relat Disord
; 74: 104706, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068370
4.
The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.
Mult Scler Relat Disord
; 57: 103364, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158470
5.
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
Mult Scler Relat Disord
; 57: 103416, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34847379
6.
Natalizumab discontinuation in a Dutch real-world cohort.
Mult Scler Relat Disord
; 52: 102974, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33990055
7.
Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Mult Scler Relat Disord
; 33: 82-87, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31174043